Novartis canned branaplam in an update that also featured details of changes to the R&D plan for iptacopan.
Novartis has delivered the coup de grâce to its ailing branaplam program, stopping (PDF) development of the splicing modulator in Huntington’s disease in the wake of a safety signal. The Big Pharma disclosed the update alongside news of the delays and discontinuations that have hit oral factor B inhibitor iptacopan.
In August, Novartis stopped dosing in a phase 2b clinical trial of branaplam after seeing early signs that the candidate may be causing peripheral neuropathy, a condition characterized by damage to the nerves outside of the brain and spinal cord. Novartis spent the rest of the year going over the data on the drug candidate before reaching a decision on the next steps.
Now, the management team has revealed it is discontinuing the program based on the assessment of the potential risk-benefit profile seen in the phase 2b study. The news is another blow for the industrywide effort to develop treatments for Huntington’s, which has in recent years suffered setbacks including the failure of Roche and Ionis Pharmaceuticals’ antisense drug tominersen in phase 3 and the temporary pause of uniQure’s high-dose gene therapy arm.
Novartis’ decision to exit the race, which follows the termination of development of branaplam in spinal muscular atrophy, makes PTC TherapeuticsPTC Therapeutics’ PTC518 the most advanced Huntington’s splicing modulator. PTC plans to share 12-week phase 2 data on the candidate in the second quarter.
Novartis canned branaplam in a fourth-quarter pipeline update that featured details of changes to the R&D plan for iptacopan, the molecule the company is developing to challenge AstraZeneca’s Alexion for the blockbuster paroxysmal nocturnal hemoglobinuria (PNH) market. The company is on track to file for approval in PNH this year, but other aspects of the strategy have slipped.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.